Skip to main content
Clinical Trials/NCT07059208
NCT07059208Not yet recruitingNot Applicable

Atrioventricular Nodal Ablation Versus Pulmonary Vein Isolation - Patient Centred Decisions

Sunshine Coast Hospital and Health Service0 sites172 target enrollmentStarted: September 1, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
172
Primary Endpoint
All cause rehospitalisation

Study Overview

Brief Summary

The goal of this clinical trial is to compare two procedural approaches to managing atrial fibrillation. The main questions it aims to answer are:

Is AF ablation or pacemaker implant and AV nodal ablation a more effective treatment approach for patients with atrial fibrillation refractory to pharmacological treatment?

What effect do these differing treatment approaches have on patient's quality of life and mental health?

Participants will:

Be randomly allocated to one of the treatment approaches. Visit the clinic 2 months, 12 months and 24 months after their procedure for a checkup, questionnaires and repeat heart ultrasounds.

Detailed Description

The goal of this trial is to compare the effectiveness and safety of pulmonary vein isolation compared with pacemaker implant and atrioventricular nodal ablation for patients with atrial fibrillation.

Patients who have been refractory to attempts at symptom control with pharmacological therapy will be eligible and will be randomised to one of the two approaches.

The primary outcome will be all cause rehospitalisation with secondary outcomes including procedural complications, echocardiographic measurements, patient reported outcomes, all cause mortality and rehospitalisation due to cardiovascular causes. These will be assessed over the 2 years following the index procedure.

The patient reported outcome measures will be the EQ5D, AF Effect on Quality of life score (AFEQT), Hospital anxiety and depression score (HADS) and Somatosensory amplification scale.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age greater than 65 years for patients with persistent atrial fibrillation or greater than 75 years for patients with paroxysmal atrial fibrillation.
  • •Unsuccessful trial of at least one pharmacological rate or rhythm control medication. This includes patients with medication refractory AF and/or intolerance to the medication(s).
  • •A resting ECG demonstrating AF with ventricular response rate >70bpm on a pharmacological rate control medication, or >90bpm while not on rate control medication.

Exclusion Criteria

  • •Previous pulmomary vein isolation, left atrial flutter ablation or atrioventricular node ablation.
  • •Not suitable for pulmonary vein isolation and/or pacemaker implant on clinical grounds.

Arms & Interventions

Pulmonary vein isolation

Active Comparator

Patients randomised to this arm would undergo catheter ablation targeted at achieving pulmonary vein isolation

Intervention: Pulmonary vein isolation (Procedure)

Pacemaker implant and atrioventricular nodal ablation

Active Comparator

Patients randomised to this arm would undergo physiological pacing followed by atrioventricular nodal ablation

Intervention: Atrioventricular nodal ablation (Procedure)

Outcomes

Primary Outcomes

All cause rehospitalisation

Time Frame: 2 years

All rehospitalisations for any reason will be included

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Matthew Tung

Principal Investigator

Sunshine Coast Hospital and Health Service

Similar Trials